MedTrace Logo

(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma

NCT01936974 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2018-02-20

Study results available
· View outcomes & findings →

Summary

To evaluate progression-free survival with two chemotherapy regimens on platinum-resistant/refractory ovarian and peritoneal carcinoma

Conditions

  • Ovarian Carcinoma
  • Fallopian Tube Carcinoma
  • Peritoneal Carcinoma

Interventions

DRUG

Gemcitabine

Patient to receive gemzar

DRUG

Bevacizumab

Patient to receive avastin

DRUG

Carboplatin

Patient to receive carboplatin

DRUG

Cisplatin

Patient to receive cisplatin

DRUG

Oxaliplatin

Patient to receive Oxaliplatin

Sponsors & Collaborators

  • Western Regional Medical Center

    lead OTHER

Principal Investigators

  • Jordan Waypa, FNP · Western Regional Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01936974 on ClinicalTrials.gov